Abstract

Aim
To develop and examine the feasibility of an online monitoring tool of depressive symptoms, suicidality and side effects.
Methods
The online tool was developed based on guideline recommendations and employed already validated and widely used measures. Quantitative data about its use, and qualitative information on its functionality and usefulness were collected from surveys, a focus group and individual interviews.
Results
Fifteen young people completed the tool between one and 12 times and reported it was easy to use. Clinicians suggested it was too long and could be completed in the waiting room to lessen impact on session time. Overall, clients and clinicians who used the tool found it useful.
Conclusions
Results show that an online monitoring tool is potentially useful as a systematic means for monitoring symptoms, but further research is needed including how to embed the tool within clinical practice. 
Introduction
Guidelines assist clinicians to provide evidence based and effective interventions for young people with depression (5-9). They consistently recommend regular monitoring of symptoms and, for those prescribed an antidepressant, of adverse effects and suicide risk given this risk is increased on antidepressants (10) (11) (12) . However, research has shown these recommendations are not uniformly implemented (13, 14) . Based on a study of barriers to monitoring (15) , a self-report tool was designed to assist clinicians to undertake adequate monitoring.
The aim of the current study was to examine the feasibility of this tool.
Methods
Setting
The Youth Mood Clinic (YMC) is part of Orygen Youth Health (OYH), a public youth mental health service for those aged 15 -24 living in the northwestern metropolitan area of Melbourne, Australia. Eighty-five percent of YMC clients have major depressive disorder; 80% receive mediation given the severity of disorder, established by the Patient Health Questionnaire (PHQ-9; (16)) and clinical assessment.
Psychiatrists regularly review clients, and case managers (clinical psychologists'; social workers; occupational therapists) deliver weekly CBT and case management. 
Participants
Design and development of the monitoring tool
The tool was based on guideline recommendations for the regular monitoring of symptoms and side effects, particularly suicidality.
Phase 1: Development
The PHQ-9 (16) was chosen to monitor depression symptoms given its use in the YMC . It has sound psychometric properties (16) and is used in those as young as 12 (17) .
While mostly used for screening, it is a useful outcome measure of depression (17) (18) (19) ..
The Suicidal Ideation Questionnaire-Junior (SIQ-JR; (20) ) was chosen to monitor suicidal ideation on the basis of a systematic review in which it was the most common tool (21) . It has sound psychometric properties (20) and is used in those aged as young as 11 (20, 22) .
A checklist of side effects was constructed using the Antidepressant Side-Effect Checklist (ASEC) and a synthesis of reported side effects from a systematic review of antidepressants in adolescents (23) .
The tool was designed to be available online; at the YMC it was available via an iPAD.
Phase 2: Refinement F o r P e e r R e v i e w 5 The Platform Team at OYH, comprised of past and present clients, participated in a focus group. Feedback included: (i) a preference for radio buttons rather than dropdown options and (ii) a preference to exclude images.
Feedback from YMC clinicians included using language consistent with the service (e.g. "case manager" rather than "clinician") and limiting free text boxes given concerns these would be used to communicate distress outside of clinic hours with the expectation of an immediate response. Participants were asked to complete the tool once a week for up to three months. Clients could fill in the tool at any location with Internet access at any time with the exception suicidal ideation items. These were completed at the beginning of their regular treatment session with their clinician on an iPad. Once completed the client handed the iPad to their clinician, with the iPad programmed to display SIQ-JR responses with an indication regarding the meaning of the scores (i.e. SIQ-JR score of >31 or a score of >4 Clinicians had no access to raw data of clients PHQ-9 and SIQ-JR scores but received a chart of these scores after 4 weeks and could choose to share this with their client. They received an email regarding side effects that were endorsed, which they could report to the treating psychiatrist for immediate action.
Clients and clinicians also filled in a survey about the functionality and usefulness of the tool. A focus group with YMC clinician's and telephone interviews with clients were conducted to further investigate these issues.
Ethics
This study received ethics approval from the Melbourne Health Research and Ethics Committee (reference number 2010.240).
Data Analysis
Frequency data and descriptive statistics were used to report on use of the tool. Analysis of qualitative data was driven by the research aims regarding functionality and usefulness and was undertaken in accordance with Braun and Clarke's methods (24) . were not involved as they see clients less frequently and were difficult to liaise with given case load and time constraints.
Results
Quantitative Data
Of the 34 clients who provided consent, six were unable to commence because a signed parental consent form was not returned. A further 13 did not commence use of the tool.
The tool was filled in by 15 clients (mean age 18.74, SD=2.65). The mean PHQ-9 score was 13.3 which indicates a moderate level of severity; 73% were on medication, They filled the tool in between one and 12 times (M = 5.33, SD = 4.08; Table 4 ). The tool was mostly completed with the clinician (Table 1) . 
Qualitative Data
Seven clients and seven clinician completed surveys, and six interviews with clients plus a focus group with clinicians (7) were undertaken. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   8 Functionality. The time taken to complete the tool was acceptable to most clients (range 2 to 10 minutes). One client reported that it took too long to complete.
All but one client reported the online format was "good", stating it was easier than having a "conversation with the case manager", and that it was "simple" to complete.
One client found it "a bit weird" because they were not used to it and two reported it was not capable of "capturing what you felt by ticking a box".
Clinicians all reported liking the tool but were concerned about its length and that too much "time [was] taken in session". Most clinicians suggested implementing the tool in the waiting room.
Usefulness. Most clients stated the tool helped them in some way. Generally it helped them to (i) understand more about their symptoms, (ii) understand how symptoms fluctuated in response to life events, and (iii) allowed them to feel more in control of managing symptoms. Two clients stated the tool helped them change their behaviour of "not eating and sleeping". Only one client said that the tool was not helpful because "it wasn't telling me anything I didn't (already) know".
No clinician showed their client graphs of their PHQ-9 or SIQ-JR scores, however, clients generally said this would have been helpful.
Clinicians commented that the tool helped them understand more about their client's risk. One clinician said that it was useful for informing treatment planning and another found it useful for engagement "particularly with clients who are reluctant to disclose information to clinicians".
Discussion
Undertaking systematic monitoring of symptoms and side effects, using an online format can be beneficial. Clients and clinicians had mostly positive feedback about the functionality and usefulness of the tool. Time taken to complete the tool was generally acceptable and clients reported it easy to use. Clients identified a particular benefit as having a greater understanding of and control over symptoms, consistent with the selfmanagement literature (25) . It was therefore surprising that clinicians did not share with their clients PHQ or SIQ scores; particularly given clients thought this would have been useful.
Clinicians reported understanding more about their client's risk via the tool. It was helpful for engaging clients, particularly those who were reluctant to disclose information, suggesting self-monitoring can foster a more collaborative relationship between clinician and clients. Given previous research (25) and feedback from clients, this collaboration may be enhanced by the careful sharing of symptom scores over the course of treatment.
However, the uptake of the tool was relatively poor indicating that further work is needed to embed the tool within clinical practice. The setting, protocols and clinical management tools already in use need to be considered as also highlighted in primary care research we have undertaken (26) . Further suggestions from clinicians were 
Abstract
Aim
To develop and examine the feasibility, functionality and usefulness of an online monitoring tool of depressive symptoms, suicidality and side effects.
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Results
Fifteen young people completed the tool between one and 12 times and reported it was easy to use. Clinicians suggested it was too long and could be completed in the waiting room to lessen impact on session time. Overall, both clients and clinicians who used the tool found the it tool useful. Clinicians reported it helped them understand more about their client's risk.
Conclusions
Results show that an online monitoring tool could is potentially be useful as a systematic means for monitoring symptoms, but further research is needed including how to work is needed to embed the tool within clinical practice. 
Introduction
The prevalence of depression in young people is high (e.g. 1, 2) and the potential negative impacts on developing and maintaining good relationships, vocational attainment and achievement are significant (2, 3). There is a high risk of self harm and suicide (4) . Therefore, it is critical that depression is effectively treated.
Guidelines assist clinicians to provide evidence based and effective interventions for young people with depression (5-9). Guidelines They consistently recommend regular monitoring of symptoms and, for those prescribed an antidepressant, regular monitoring of adverse effects and suicide related behaviour suicide risk given this risk is increased one known risks of these behaviours for young people on antidepressants (10-12).
However, research has shown that such monitoring isthese recommendations are not uniformly implemented (13, 14) . Based on a study of barriers to monitoring (15) , including a perceived lack of time and expertise, a self-report tool was designed with the view to assisting clinicians to ensure undertake adequate monitoring by the regular collection of standardised information.
The aim of the current study was to examine the feasibility , functionality and usefulness of this tool. Psychiatrists regularly review clients, and case managers (clinical psychologists'; social workers; occupational therapists) deliver weekly CBT and case management.
Methods
Setting
Participants
New or already established lients of YMC clients and . In addition, all clinicians in the YMC were invited to participate.
Design and development of the monitoring tool
The content of the tool was based on guideline recommendations for the regular monitoring of that state that symptoms and side effects, particularly suicidality, be assessed regularly.
Phase 1: Development
The Patient Health QuestionnairePHQ-9 (PHQ-9; (16)) was chosen to monitor depression symptoms given its use in the as the YMC already used it. It has sound psychometric properties (16) and is used in those as young as 12 (17) . While mostly used for screening, it is also a useful outcome measure of depression (17) (18) (19) . Clients 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The Suicidal Ideation Questionnaire-Junior (SIQ-JR; (20) ) was chosen to monitor suicidal ideation on the basis of a systematic review in which it was the most commonly common used tool (21) . It has sound psychometric properties (20) and is used in those aged as young as 11 (20, 22) .
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A checklist of side effects was constructed on the basis ofusing the Antidepressant SideEffect Checklist (ASEC) and a synthesis of reported side effects in trials included infrom a systematic review of selective serotonin reuptake inhibitors (SSRIs)antidepressants in adolescents (23).
Phase 2: Refinement
The Platform Team at OYH, comprised of past or and present clients, participated in a focus group. Feedback included: (i) a preference for grids of radio buttons rather than dropdown options and (ii) a preference to exclude images from the tool.
Feedback from consultation with YMC clinicians included using language that was consistent with the service (e.g. "case manager" rather than "clinician") and limiting free text boxes given concerns these would be used to communicate distress outside of clinic hours with the expectation of an immediate response. Clinicians had no access to raw data ofreceived a chart of their clients PHQ-9 and SIQ-JR scores but received a chart of these scores after 4 weeks and could choose to share this graph with their client. They received an email regarding side effects that were endorsed, which they could report to the treating psychiatrist for immediate action. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Data Analysis
Frequency data and descriptive statistics were used to report on clients' use of the tool.
Analysis of qualitative data was driven by the research aims regarding functionality and usefulness and was of the tool. This analysis was undertaken in accordance with Braun and Clarke's methods (24) .
Results
Quantitative Data
All seven YMC case managers in the YMC, all allied health professionals and 34 of their clients consented to participate. in the study. Doctors were not involved as they see clients less frequently and were difficult to liaise with given case load and time constraints. Table 4 ). The tool was mostly completed with the clinician (Table 1) . 
Qualitative Data
Seven clients and seven clinician completed surveys, and six telephone interviews with clients and plus a focus group with clinicians (7) were undertaken.
Functionality. The time taken to complete the tool was acceptable to most clients (range 2 to 10 minutes). One client reported that it took too long to complete.
All but one client reported the online format was "good", stating it was easier than having a "conversation with the case manager", and that it was "simple" to complete. One client found it "a bit weird" because they were not used to it and two clients reported that some questions wereit was limiting and not capable of "capturing what you felt by ticking a box".
Clinicians all reported liking the tool but . However, they were concerned about its length and that too much "time [was] taken in session". Most clinicians suggested implementing the tool in the waiting room.
Usefulness. Most clients stated some way that the tool helped them in some way.
Clients Ggenerally reported it helped them to (i) understand more about their symptoms,
(ii) understand how symptoms fluctuated in response to life events, and (iii) allowed them to feel more in control of managing symptoms. Two clients stated the tool helped them to monitor their mood and change their behaviour of "not eating and sleeping" appropriately. Only one client said that the tool was not helpful because "it wasn't telling me anything I didn't (already) know".
Clinicians commented that the tool was useful and helped them to understand more about their client's risk. One clinician said that the toolit was useful for informing treatment planning and another found the toolit useful for engagement "particularly with clients who are reluctant to disclose information to clinicians". Time taken to complete the tool was generally acceptable and clients reported finding it easy to use. Clients identified aA particular benefit as having identified by clients was having a greater understanding of and control over their symptoms and an increased sense of control of them, . This is consistent with the self-management literature (25) . It was therefore surprising that clinicians did not share with their clients PHQ or SIQ scores; particularly given clients thought this would have been useful.
Clinicians reported that the tool helped them understanding more about their client's risk via the tool. It was also found to be helpful for engaging with clients, such asparticularly those who were reluctant to disclose information, . This feedback suggestssuggesting that self-monitoring helped tocan foster a more collaborative relationship between clinician and clients. Given previous research (25) and feedback from clients, this collaboration may be enhanced by the careful sharing of symptom scores over the course of treatment.
On the other handHowever, the uptake of the tool was relatively poor indicating that further work is needed to successfully embed the tool within clinical practice. (26)The setting, protocols and clinical management tools already in use need to be considered as (26) . Further Useful suggestions from clinicians were consistent with previous research (27) and included reducing the length of the tool and making it available forhaving it completedion in the waiting room. . This is consistent with other recent findings (27) . These improvements, implementation tailored to individual settings, as well as providing evidence of utility in terms of improving clinical practice via weekly feedback of scores (as demonstrated in previous research (28)) would improve the likelihood that the tool would improve adherence to guideline recommendations about monitoring. Further testing of the tool in this regard is required. Making the graph illustrating weekly depressive and suicidal symptom scores available to clients as well as clinicians may be useful.
The clinicians in the study were all allied health professionals and Nno doctors provided feedback and . Further, surveys and phone interviews were not completed by all clients who used the tool, so the generalisability may be limited; investigating how doctors, younger clients and clients being treated in different settings use the tool is important for future studies. however, results show the tool is functional, potentially useful and may assist clinicians to undertake monitoring according to guideline recommendations. 21 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 2. All participants were in a program for those with moderate to severe depression. How is this determination of severity currently made? Please report also whether all of the participants in the study were on medication. It would also be useful to provide a brief description of the sort of treatment participating clients were receiving at this service.
We have included the severity ratings based on baseline PHQ-9 scores and the number who were on medication in the results. We have include a description of the treatment young people receive in the YMC in the methods section.
3. Please provide the age range and mean age for clients. Also provide a suggestion as to the age range that the tool is suitable for. As a comment, I am also interested in whether younger clients (around 15 years) may respond differently to the tool in comparison to those clients aged around 24 years of age. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 4. Please provide some further information as to how clinicians received information from the survey. It is stated they receive a chart of the client's PHQ-9 and SIQ-JR after 4 weeks, but do they have access to the raw data before this time. It is stated that the suicide items are completed in the presence of the clinician so they have immediate access to that. However, it is unclear how the clinicians receive the information from the survey. For example, how do they know if the client has completed the survey, how quickly can they access the information, what format is data provided in, how do they feed back this information to clients, and how quickly is this feedback provided? In addition, how is the data from external locations with Internet access obtained?
YMC is part of Orygen
We 6. If this tool is to be used more broadly, then there will be many young people who will not be on antidepressant medication so I assume that part of the checklist would be left blank.
Yes, that is correct. Programming can ensure that this section is turned off or on. We have indicated in the discussion that it may be useful to investigate how those on medication use the tool.
7. It is also stated that no clinicians showed their clients graphs of their data. Can you comment on the reasons for this? In terms of therapeutic process, I think it is essential that clients are provided with graphs or other useful visual aids about their own symptoms on which they are reporting. This helps build therapeutic alliance and also encourages clients to play a more active role in their own health care. This could also build mental health literacy and perhaps assist clients to identify more quickly when there may be a decline in functioning and perhaps learn some strategies to address this. Can you also discuss how the feedback to clients can be built into this tool? 9. While I fully support the idea of regular monitoring of symptoms and medications, I
am not sure whether a monitoring tool such as the one developed in the current study will address the issue from the research findings that regular monitoring is not uniformly implemented. It is also known from research that clinicians who monitor clients' progress and their own performance, achieve better therapy outcomes. It is concerning therefore, that symptoms of depression and response to treatment are not regularly reviewed, given they are key indicators of progress and treatment effectiveness. Further given the increased risk for suicidal ideation and intent associated with depression, it is also necessary to undertake some type of regular check with clients to assess their ongoing status. Given there are quite brief screening measures that already exist, I am not sure that it is the lack of an evaluation tool that is the key issue here. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 11 . As a further suggestion, it would be useful if you could introduce this evaluation tool into your service as a larger trial and also collect brief satisfaction data from the clients (this could be a simple tick box format at the end of the survey asking about the usefulness of the survey, how difficult they found it to complete, and likelihood to continuing using the tool). Additional focus groups/interviews with clinicians could examine implementation of the tool, barriers/difficulties, and impact on treatment. This would make a very good addition to the current paper and should allow for some clearer suggestions to be made about the tool and its delivery.
We have received funding to implement the tool, refined on the basis of this pilot study, into this service, a headspace (enhanced primary care) and general practice and have included collection of data with regard to satisfaction. This study is underway and results will be available next year. We will publish the results of this study in separate papers, given the tool is slightly different and that we have taken on board the findings of this study (which are confirmed by this reviewer) with regards to the implementation of the tool across a range of services. We think it is important to publish data on the development and pilot study of the first version of the tool to provide some context to its ongoing development and implementation into practice.
Reviewer: 2 1. The paper describes a first step towards the design of an etool for assessment of depression. At this stage, it is limited to programming of existing instruments, and requires web access, and has a substantial number of questions for repeated monitoring. Adherence to monitoring appears limited as yet, and acceptability also has room of significant improvement.
Development (or adaptation) of a shorter yet valid and sensitive instrument--ideally programmed for use on both mobile phones an iPads, and in an app format that could be used when web connections are unavailable--would be a significant contribution to the field. The current data could be reported in a paper that describes further developments along these lines.
We agree that more development is required, including further testing and have in mind that the end result could be connectivity to such a tool via a mobile phone app. Given the innovation embedded in this program of research we think it is important to publish data on the development of the tool and the learning's from this pilot study given others may well be developing similar tools. We are currently testing a version of this tool, modified on the basis of this pilot study, in a larger sample and hope to publish findings in 2015.
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